ARK Investment Management LLC boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,595,865 shares of the company's stock after purchasing an additional 237,772 shares during the period. Twist Bioscience accounts for about 2.2% of ARK Investment Management LLC's investment portfolio, making the stock its 13th biggest holding. ARK Investment Management LLC owned 9.43% of Twist Bioscience worth $260,040,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of the stock. State Street Corp boosted its position in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Geode Capital Management LLC boosted its position in Twist Bioscience by 1.9% during the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock valued at $61,807,000 after purchasing an additional 26,145 shares during the last quarter. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the third quarter valued at approximately $43,992,000. Wellington Management Group LLP boosted its position in Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock valued at $36,042,000 after purchasing an additional 521,272 shares during the last quarter. Finally, Fred Alger Management LLC boosted its position in Twist Bioscience by 17.1% during the third quarter. Fred Alger Management LLC now owns 767,149 shares of the company's stock valued at $34,660,000 after purchasing an additional 112,272 shares during the last quarter.
Analyst Upgrades and Downgrades
Several brokerages recently commented on TWST. TD Cowen reissued a "buy" rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird upped their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. Finally, Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $54.40.
Check Out Our Latest Analysis on TWST
Insiders Place Their Bets
In other Twist Bioscience news, SVP Paula Green sold 860 shares of the firm's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $45,322.00. Following the transaction, the senior vice president now owns 133,715 shares in the company, valued at $7,046,780.50. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Chess sold 2,940 shares of the firm's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. This trade represents a 13.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,180 shares of company stock worth $1,821,971 in the last 90 days. Company insiders own 3.01% of the company's stock.
Twist Bioscience Stock Performance
Shares of NASDAQ TWST traded up $0.26 during trading hours on Friday, reaching $38.82. 935,132 shares of the stock were exchanged, compared to its average volume of 881,875. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -11.49 and a beta of 1.87. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The stock's fifty day simple moving average is $47.64 and its 200 day simple moving average is $45.62.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm's quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.75) earnings per share. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.
Twist Bioscience Profile
(
Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Articles
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
